Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous cellular therapies for neurodegenerative diseases including ALS, progressive multiple sclerosis, and Alzheimer's disease. Its proprietary NurOwn platform induces bone marrow-derived mesenchymal stem cells to secrete neurotrophic factors, modulate neuroinflammation, and promote neuronal survival. NurOwn has completed Phase 3 ALS and Phase 2 PMS trials and received FDA SPA agreement for a planned Phase 3b ALS trial.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001104659-26-037927 | EDGAR | 94K words |
| 2025-03-31 | 2024-12-31 | 0001410578-25-000545 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001410578-24-000385 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001410578-23-000426 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001410578-22-000554 | EDGAR | — |
| 2021-02-04 | 2020-12-31 | 0001104659-21-011928 | EDGAR | — |
| 2020-02-18 | 2019-12-31 | 0001104659-20-022244 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001144204-19-017041 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001144204-18-013470 | EDGAR | — |
| 2017-03-29 | 2016-12-31 | 0001144204-17-017265 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001104659-25-112701 | EDGAR | 27K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001782 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001347 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001410578-24-002000 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001410578-24-001400 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001410578-24-000820 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001410578-23-002443 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001831 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001410578-23-001157 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003271 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001410578-22-002510 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001410578-22-001572 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001104659-26-037760 | EDGAR | 3K words |
| 2026-02-27 | 0001104659-26-021613 | EDGAR | — |
| 2026-02-13 | 0001104659-26-015262 | EDGAR | — |
| 2026-01-09 | 0001104659-26-002494 | EDGAR | — |
| 2025-11-14 | 0001104659-25-112682 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107833 | EDGAR | — |
| 2025-08-14 | 0001104659-25-078116 | EDGAR | — |
| 2025-07-17 | 0001104659-25-068709 | EDGAR | — |
| 2025-06-25 | 0001104659-25-062595 | EDGAR | — |
| 2025-06-16 | 0001104659-25-059900 | EDGAR | — |
382 total filings indexed. 350 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001137883 |
| Ticker | BCLI |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Headquarters | United States (specific city not mentioned); R&D center in Petach Tikva, Israel |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report